Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 16

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Protective role of mirtazapine in adult female Mecp2(+/-) mice and patients with Rett syndrome

Flores Gutiérrez, Javier, De Felice, Claudio, Natali, Giulia, Leoncini, Silvia, Signorini, Cinzia, Hayek, Joussef, Tongiorgi, Enrico · 2020 · Journal of Neurodevelopmental Disorders

Abstract

Background: Rett syndrome (RTT), an X-linked neurodevelopmental rare disease mainly caused by MECP2 -gene mutations, is a prototypic intellectual disability disorder. Reversibility of RTT-like phenotypes in an adult mouse model lacking the Mecp2- gene has given hope of treating the disease at any age. However, adult RTT patients still urge for new treatments. Given the relationship between RTT and monoamine deficiency, we investigated mirtazapine (MTZ), a noradrenergic and specific-serotonergic antidepressant, as a potential treatment. Methods: Adult heterozygous- Mecp2 (HET) female mice (6-months old) were treated for 30 days with 10 mg/kg MTZ and assessed for general health, motor skills, motor learning, and anxiety. Motor cortex, somatosensory cortex, and amygdala were analyzed for parvalbumin expression. Eighty RTT adult female patients harboring a pathogenic MECP2 mutation were randomly assigned to treatment to MTZ for insomnia and mood disorders (mean age = 23.1 ± 7.5 years, range = 16–47 years; mean MTZ-treatment duration = 1.64 ± 1.0 years, range = 0.08–5.0 years). Rett clinical severity scale (RCSS) and motor behavior assessment scale (MBAS) were retrospectively analyzed. Results: In HET mice, MTZ preserved motor learning from deterioration and normalized parvalbumin levels in the primary motor cortex. Moreover, MTZ rescued the aberrant open-arm preference behavior observed in HET mice in the elevated plus-maze (EPM) and normalized parvalbumin expression in the barrel cortex. Since whisker clipping also abolished the EPM-related phenotype, we propose it is due to sensory hypersensitivity. In patients, MTZ slowed disease progression or induced significant improvements for 10/16 MBAS-items of the M1 social behavior area: 4/7 items of the M2 oro-facial/respiratory area and 8/14 items of the M3 motor/physical signs area. Conclusions: This study provides the first evidence that long-term treatment of adult female heterozygous Mecp2 tm1.1Bird mice and adult Rett patients with the antidepressant mirtazapine is well tolerated and that it protects from disease progression and improves motor, sensory, and behavioral symptoms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s11689-020-09328-z

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 62

  1. Hagberg B, Aicardi J, Dias K, Ramos O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett’s syndrome: report of 35 cases. Ann Neurol. 1983 Oct;14(4):471–9. · DOI · Paper page
  2. Rett A. On a remarkable syndrome of cerebral atrophy associated with hyperammonaemia in childhood. Wien Med Wochenschr. 2016 Sep;166(11–12):322–4. · doi:10.1007/s10354-016-0492-8
  3. Leonard H, Cobb S, Downs J. Clinical and biological progress over 50 years in Rett syndrome. Nat Rev Neurol. 2017 Jan;13(1):37–51. · DOI · Paper page
  4. Fehr S, Bebbington A, Nassar N, Downs J, Ronen GM, De Klerk N, et al. Trends in the diagnosis of Rett syndrome in Australia. Pediatr Res. 2011 Sep;70(3):313–9. · DOI
  5. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999 Oct;23(2):185–8. · DOI · Paper page
  6. Connolly DR, Zhou Z. Genomic insights into MeCP2 function: a role for the maintenance of chromatin architecture. Curr Opin Neurobiol. 2019 Dec;59:174–9. · DOI
  7. Della Ragione F, Vacca M, Fioriniello S, Pepe G, D’Esposito M. MECP2, a multi-talented modulator of chromatin architecture. Brief Funct Genomics. 2016 Jun;12:elw023. · DOI
  8. Przanowski P, Wasko U, Zheng Z, Yu J, Sherman R, Zhu LJ, et al. Pharmacological reactivation of inactive X-linked Mecp2 in cerebral cortical neurons of living mice. Proc Natl Acad Sci. 2018;115(31):7991–6. · DOI
  9. Erlandson A, Hagberg B. MECP2 abnormality phenotypes: clinicopathologic area with broad variability. J Child Neurol. 2005;20(9):727–32. · DOI
  10. Neul KWE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68(6):944–50. · DOI · Paper page
  11. Roze E, Cochen V, Sangla S, Bienvenu T, Roubergue A, Leu-Semenescu S, et al. Rett syndrome: an overlooked diagnosis in women with stereotypic hand movements, psychomotor retardation, parkinsonism, and dystonia? Mov Disord Off J Mov Disord Soc. 2007;22(3):387–9. · DOI
  12. Ip JPK, Mellios N, Sur M. Rett syndrome: insights into genetic, molecular and circuit mechanisms. Nat Rev Neurosci. 2018 Jun;19(6):368–82. · DOI · Paper page
  13. Tarquinio DC, Hou W, Neul JL, Kaufmann WE, Glaze DG, Motil KJ, et al. The changing face of survival in Rett syndrome and MECP2-related disorders. Pediatr Neurol. 2015 Nov;53(5):402–11. · DOI
  14. Reiss AL, Faruque F, Naidu S, Abrams M, Beaty T, Bryan RN, et al. Neuroanatomy of Rett syndrome: a volumetric imaging study. Ann Neurol. 1993 Aug;34(2):227–34. · DOI · Paper page
  15. Zoghbi HY. Rett syndrome and the ongoing legacy of close clinical observation. Cell. 2016 Oct;167(2):293–7. · DOI
  16. Clarke AJ, Abdala Sheikh AP. A perspective on ‘cure’ for Rett syndrome. Orphanet J Rare Dis. 2018 02;13(1):44. · DOI
  17. Katz DM, Berger-Sweeney JE, Eubanks JH, Justice MJ, Neul JL, Pozzo-Miller L, et al. Preclinical research in Rett syndrome: setting the foundation for translational success. Dis Model Mech. 2012 Nov 1;5(6):733–45. · DOI · Paper page
  18. Samaco RC, Mandel-Brehm C, Chao H-T, Ward CS, Fyffe-Maricich SL, Ren J, et al. Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities. Proc Natl Acad Sci. 2009 Dec 22;106(51):21966–71. · DOI · Paper page
  19. Santos M, Summavielle T, Teixeira-Castro A, Silva-Fernandes A, Duarte-Silva S, Marques F, et al. Monoamine deficits in the brain of methyl-CpG binding protein 2 null mice suggest the involvement of the cerebral cortex in early stages of Rett syndrome. Neuroscience. 2010 Oct;170(2):453–67. · DOI
  20. Temudo T, Rios M, Prior C, Carrilho I, Santos M, Maciel P, et al. Evaluation of CSF neurotransmitters and folate in 25 patients with Rett disorder and effects of treatment. Brain and Development. 2009 Jan;31(1):46–51. · DOI
  21. Roux J-C, Dura E, Moncla A, Mancini J, Villard L. Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome. Eur J Neurosci. 2007;8. · DOI
  22. Zanella S, Mebarek S, Lajard A-M, Picard N, Dutschmann M, Hilaire G. Oral treatment with desipramine improves breathing and life span in Rett syndrome mouse model. Respir Physiol. 2008;6. · DOI
  23. Mancini J, Dubus J-C, Jouve E, Roux J-C, Franco P, Lagrue E, et al. Effect of desipramine on patients with breathing disorders in RETT syndrome. Ann Clin Transl Neurol. 2018 Feb;5(2):118–27. · DOI
  24. Szegedi A, Schwertfeger N. Mirtazapine: a review of its clinical efficacy and tolerability. Expert Opin Pharmacother. 2005 Apr;6(4):631–41. · DOI
  25. Burrows GD, Kremer CME. Mirtazapine: clinical advantages in the treatment of depression. J Clin Psychopharmacol. 1997 Apr;17:34S–9S. · DOI
  26. Hartmann P. Mirtazapine: a newer antidepressant. Am Fam Physician. 1999 Jan 1;59(1):159–61.
  27. Bittolo T, Raminelli CA, Deiana C, Baj G, Vaghi V, Ferrazzo S, et al. Pharmacological treatment with mirtazapine rescues cortical atrophy and respiratory deficits in MeCP2 null mice. Sci Rep. 2016 Apr;6(1):19796. · DOI · Paper page
  28. Anttila SAK, Leinonen EVJ. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2006;7(3):249–64. · DOI · Paper page
  29. Nair A, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27. · DOI · Paper page
  30. Deacon RMJ. Measuring motor coordination in mice. J Vis Exp. 2013;75:2609.
  31. Deacon RM. Assessing nest building in mice. Nat Protoc. 2006;1(3):1117–9. · DOI · Paper page
  32. Vogel Ciernia A, Pride MC, Durbin-Johnson B, Noronha A, Chang A, Yasui DH, et al. Early motor phenotype detection in a female mouse model of Rett syndrome is improved by cross-fostering. Hum Mol Genet. 2017 May 15;26(10):1839–54. · DOI
  33. Paxinos G, Franklin K. The mouse brain in stereotaxic coordinates, compact. 3rd Edition. Academic Press; 2008. 256 p.
  34. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012 Jul;9(7):676–82. · DOI · Paper page
  35. Renieri A, Mari F, Mencarelli MA, Scala E, Ariani F, Longo I, et al. Diagnostic criteria for the Zappella variant of Rett syndrome (the preserved speech variant). Brain and Development. 2009 Mar;31(3):208–16. · DOI
  36. Samaco RC, McGraw CM, Ward CS, Sun Y, Neul JL, Zoghbi HY. Female Mecp2+/− mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies. Hum Mol Genet. 2013;22(1):96–109. · DOI · Paper page
  37. Mount RH, Hastings RP, Reilly S, Cass H, Charman T. Behavioural and emotional features in Rett syndrome. Disabil Rehabil. 2001 Mar 15;23(3–4):129–38.
  38. Barnes KV, Coughlin FR, O’Leary HM, Bruck N, Bazin GA, Beinecke EB, et al. Anxiety-like behavior in Rett syndrome: characteristics and assessment by anxiety scales. J Neurodev Disord. 2015 Dec;7(1):30. · DOI
  39. Jiang X, Lachance M, Rossignol E. Involvement of cortical fast-spiking parvalbumin-positive basket cells in epilepsy. Prog Brain Res. 2016;226:81–126. · DOI
  40. Permyakov EA, Uversky VN, Permyakov SE. Parvalbumin as a pleomorphic protein. Curr Protein Pept Sci. 2017;18(8):780–94. · DOI
  41. Morello N, Schina R, Pilotto F, Phillips M, Melani R, Plicato O, et al. Loss of Mecp2 causes atypical synaptic and molecular plasticity of parvalbumin-expressing interneurons reflecting Rett syndrome–like sensorimotor defects. eneuro. 2018;5(5):ENEURO.0086-18.2018. · DOI
  42. Kishi N, Macklis JD. MeCP2 functions largely cell-autonomously, but also non-cell-autonomously, in neuronal maturation and dendritic arborization of cortical pyramidal neurons. Exp Neurol. 2010 Mar;222(1):51–8. · DOI
  43. Karsten J, Hagenauw LA, Kamphuis J, Lancel M. Low doses of mirtazapine or quetiapine for transient insomnia: a randomised, double-blind, cross-over, placebo-controlled trial. J Psychopharmacol (Oxf). 2017;31(3):327–37. · DOI
  44. FitzGerald PM, Jankovic J, Percy AK. Rett syndrome and associated movement disorders. Mov Disord. 1990;5(3):195–202. · DOI
  45. Wahlsten D. Chapter 10 - Domains and Test Batteries. In: Wahlsten D, editor. Mouse behavioral testing [Internet]. London: Academic Press; 2011 [cited 2020 Jul 18]. p. 157–75. Available from: http://www.sciencedirect.com/science/article/pii/B9780123756749100102. · doi:10.1016/b978-0-12-375674-9.10010-2
  46. Dutta S, Sengupta P. Men and mice: relating their ages. Life Sci. 2016 May;152:244–8. · DOI · Paper page
  47. Moretti P, Bouwknecht JA, Teague R, Paylor R, Zoghbi HY. Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome. Hum Mol Genet. 2005 Jan 15;14(2):205–20. · DOI · Paper page
  48. Pearson BL, Defensor EB, Caroline Blanchard D, Blanchard RJ. Applying the ethoexperimental approach to neurodevelopmental syndrome research reveals exaggerated defensive behavior in Mecp2 mutant mice. Physiol Behav. 2015 Jul;146:98–104. · DOI
  49. Bhattacherjee A, Winter M, Eggimann L, Mu Y, Gunewardena S, Liao Z, et al. Motor, somatosensory, viscerosensory and metabolic impairments in a heterozygous female rat model of Rett syndrome. Int J Mol Sci. 2017;19(1):97. · DOI
  50. Bhattacherjee A, Mu Y, Winter MK, Knapp JR, Eggimann LS, Gunewardena SS, et al. Neuronal cytoskeletal gene dysregulation and mechanical hypersensitivity in a rat model of Rett syndrome. Proc Natl Acad Sci. 2017 Aug 15;114(33):E6952–61. · DOI
  51. Symons FJ, Barney CC, Byiers BJ, McAdams BD, Foster SXYL, Feyma TJ, et al. A clinical case–control comparison of epidermal innervation density in Rett syndrome. Brain Behav. 2019 May;9(5):e01285. · DOI
  52. Downs J, Géranton SM, Bebbington A, Jacoby P, Bahi-Buisson N, Ravine D, et al. Linking MECP2 and pain sensitivity: the example of Rett syndrome. Am J Med Genet A. 2010 May;152A(5):1197–205. · DOI
  53. Symons FJ, Byiers B, Tervo RC, Beisang A. Parent-reported pain in Rett syndrome. Clin J Pain. 2013;29(8):744–6. · DOI
  54. Barney CC, Feyma T, Beisang A, Symons FJ. Pain experience and expression in Rett syndrome: subjective and objective measurement approaches. J Dev Phys Disabil. 2015 Aug;27(4):417–29. · DOI
  55. Cardin JA, Carlén M, Meletis K, Knoblich U, Zhang F, Deisseroth K, et al. Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature. 2009 Jun;459(7247):663–7. · DOI · Paper page
  56. Kimbrough A, de Guglielmo G, Kononoff J, Kallupi M, Zorrilla EP, George O. CRF 1 receptor-dependent increases in irritability-like behavior during abstinence from chronic intermittent ethanol vapor exposure. Alcohol Clin Exp Res. 2017;41(11):1886–95. · DOI
  57. Riittinen M-L, Lindroos F, Kimanen A, Pieninkeroinen E, Pieninkeroinen I, Sippola J, et al. Impoverished rearing conditions increase stress-induced irritability in mice: impoverished rearing increases irritability. Dev Psychobiol. 1986;19(2):105–11. · DOI
  58. Carotenuto M, Esposito M, D’Aniello A, Rippa CD, Precenzano F, Pascotto A, et al. Polysomnographic findings in Rett syndrome: a case–control study. Sleep Breath. 2013 Mar;17(1):93–8. · DOI
  59. Ammanuel S, Chan WC, Adler DA, Lakshamanan BM, Gupta SS, Ewen JB, et al. Heightened delta power during slow-wave-sleep in patients with Rett syndrome associated with poor sleep efficiency. Ferri R, editor. PLOS ONE. 2015 Oct 7;10(10):e0138113. · DOI
  60. Young D, Nagarajan L, de Klerk N, Jacoby P, Ellaway C, Leonard H. Sleep problems in Rett syndrome. Brain and Development. 2007 Nov;29(10):609–16. · DOI
  61. Buchanan CB, Stallworth JL, Scott AE, Glaze DG, Lane JB, Skinner SA, et al. Behavioral profiles in Rett syndrome: data from the natural history study. Brain and Development. 2019 Feb;41(2):123–34. · DOI
  62. Corchón S, Carrillo-López I, Cauli O. Quality of life related to clinical features in patients with Rett syndrome and their parents: a systematic review. Metab Brain Dis. 2018 Dec;33(6):1801–10. · DOI

Cited by

See all 16

Metadata

Authors
Flores Gutiérrez, J., De Felice, C., Natali, G., Leoncini, S., Signorini, C., Hayek, J., & Tongiorgi, E.
Venue
Journal of Neurodevelopmental Disorders
Published
2020-09-28
Volume
12
Issue
1
ISSN
  • 1866-1947
  • 1866-1955
Cited by
16
References
10
Language
en
Licence
Funders
Associazione Italiana Rett Onlus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Protective role of mirtazapine in adult female Mecp2(+/-) mice and patients with Rett syndrome. https://app.cochat.ai/papers/10.1186/s11689-020-09328-z
The paper
Flores Gutiérrez, J., De Felice, C., Natali, G., Leoncini, S., Signorini, C., Hayek, J., & Tongiorgi, E. (2020). Protective role of mirtazapine in adult female Mecp2(+/-) mice and patients with Rett syndrome. Journal of Neurodevelopmental Disorders. https://doi.org/10.1186/s11689-020-09328-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.